Hina Patel
NSW Ambulance · 56 works · 934 citations · h-index 13
Top works
- Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
- Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
- Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
- Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol
- IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
- Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
- Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
- Know the name: acute epiploic appendagitis—CT findings and review of literature
- The X factor: Lack of bleeding after an acute apixaban overdose
- Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
- Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis
- A need for standardization in visual acuity measurement
- Is There a Role for Fluconazole in the Treatment of Vulvovaginal Candidiasis?
- Multicenter Evaluation of Ondansetron Use in Hospitalized Oncology Patients
- Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
- Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
- Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
- IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).
- Longitudinal impact of a pre‐populated default quantity on emergency department opioid prescriptions
- The X factor: Lack of bleeding after an acute apixaban overdose